Advertisement
Advertisement

INSM

INSM logo

Insmed, Inc.

101.35
USD
Sponsored
-3.65
-3.48%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

102.08

+0.73
+0.72%

Insmed, Inc. Profile

About

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Info & Links

CEO

William H. Lewis

Headquarters

700 US Highway 202/206
Bridgewater, NJ 08807, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.insmed.com

Auditor

Ernst & Young LLP

Share holders

140

Employees

1,664

Insmed, Inc. Statistics

Valuation Measures

Market Capitalization2

22.13B

Enterprise Value

22.11B

Enterprise Value/EBITDA(ttm)

-19.65

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

56.80

Price to Book(mrq)

46.06

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

78.39%

Operating Margin(ttm)

-210.54%

Profit Margin(ttm)

-240.09%

Return on Equity(ttm)

-168.36%

Return on Invested Capital(ttm)

-88.48%

Return on Assets(ttm)

-57.33%

Income Statement

Revenue(ttm)

819.56M

Revenue Per Share(ttm)

3.78

Gross Profit(ttm)

670.48M

EBITDA(ttm)3

-1.13B

Net Income Available to Common(ttm)

-1.18B

Diluted EPS(ttm)

-6.41

Share Statistics

Beta (5Y Monthly)

1.10

52-Week Change

54.43%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

216.75M

Dividend Yield

0.00%

Float4

209.38M

% Held by Insiders

3.00%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

1.22B

Total Cash Per Share(mrq)

5.64

Total Debt(mrq)

565.48M

Total Debt/Equity(mrq)

76.46%

Current Ratio(mrq)

3.83%

Quick Ratio(mrq)

3.54%

Book Value Per Share(mrq)

3.45

Cash Flow

Operating Cash Flow Per Share(ytd)

-4.70

Free Cash Flow(ytd)

-967.58M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement